KR960029335A - 9-치환된 2-(2-n-알콕시페닐)-푸린-6- 온 - Google Patents

9-치환된 2-(2-n-알콕시페닐)-푸린-6- 온 Download PDF

Info

Publication number
KR960029335A
KR960029335A KR1019960001003A KR19960001003A KR960029335A KR 960029335 A KR960029335 A KR 960029335A KR 1019960001003 A KR1019960001003 A KR 1019960001003A KR 19960001003 A KR19960001003 A KR 19960001003A KR 960029335 A KR960029335 A KR 960029335A
Authority
KR
South Korea
Prior art keywords
carbon atoms
straight
branched chain
hydrogen
group
Prior art date
Application number
KR1019960001003A
Other languages
English (en)
Korean (ko)
Inventor
니뵈너 울리히
비쇼프 에르빈
슈츠 헬무쓰
페르쯔보른 엘리자베스
쉬람 마티아스
Original Assignee
클라우스 로이터· 귄터 슈마허
바이엘 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 클라우스 로이터· 귄터 슈마허, 바이엘 악티엔게젤샤프트 filed Critical 클라우스 로이터· 귄터 슈마허
Publication of KR960029335A publication Critical patent/KR960029335A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1019960001003A 1995-01-19 1996-01-18 9-치환된 2-(2-n-알콕시페닐)-푸린-6- 온 KR960029335A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19501480.4 1995-01-19
DE19501480A DE19501480A1 (de) 1995-01-19 1995-01-19 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one

Publications (1)

Publication Number Publication Date
KR960029335A true KR960029335A (ko) 1996-08-17

Family

ID=7751828

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960001003A KR960029335A (ko) 1995-01-19 1996-01-18 9-치환된 2-(2-n-알콕시페닐)-푸린-6- 온

Country Status (30)

Country Link
US (1) US5866571A (es)
EP (1) EP0722943A1 (es)
JP (1) JPH08231546A (es)
KR (1) KR960029335A (es)
CN (1) CN1138583A (es)
AR (1) AR002704A1 (es)
AU (1) AU4097796A (es)
BG (1) BG61729B1 (es)
BR (1) BR9600149A (es)
CA (1) CA2167349A1 (es)
CO (1) CO4700524A1 (es)
CZ (1) CZ16896A3 (es)
DE (1) DE19501480A1 (es)
EE (1) EE9600020A (es)
FI (1) FI960226A (es)
HR (1) HRP960009A2 (es)
HU (1) HUP9600107A3 (es)
IL (1) IL116771A (es)
MA (1) MA23779A1 (es)
NO (1) NO960221L (es)
NZ (1) NZ280829A (es)
PE (1) PE10597A1 (es)
PL (1) PL312353A1 (es)
SG (1) SG47379A1 (es)
SK (1) SK7696A3 (es)
SV (1) SV1996000004A (es)
TN (1) TNSN96005A1 (es)
TR (1) TR199600701A2 (es)
YU (1) YU2896A (es)
ZA (1) ZA96399B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6064072A (en) * 1997-05-12 2000-05-16 Cymer, Inc. Plasma focus high energy photon source
DE19838300A1 (de) * 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
AUPQ515700A0 (en) * 2000-01-19 2000-02-10 Fujisawa Pharmaceutical Co., Ltd. Imidazole compounds
ATE552013T1 (de) * 2000-09-06 2012-04-15 Mitsubishi Tanabe Pharma Corp Zubereitungen zur oralen anwendung
CA2437754C (en) * 2001-02-15 2010-05-18 Tanabe Seiyaku Co., Ltd. Tablets quickly disintegrated in oral cavity
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
DE60222931T2 (de) * 2001-12-13 2008-07-10 Asubio Pharma Co., Ltd. Pyrazolopyrimidinonderivate mit pde7-hemmender wirkung
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
EP1494997A4 (en) * 2002-04-05 2007-04-11 Merck & Co Inc SUBSTITUTED ARYLAMID
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
DE19501480A1 (de) 1996-07-25
IL116771A (en) 1999-06-20
AR002704A1 (es) 1998-04-29
YU2896A (sh) 1999-03-04
HUP9600107A3 (en) 1999-06-28
NZ280829A (en) 1998-04-27
IL116771A0 (en) 1996-05-14
EP0722943A1 (de) 1996-07-24
US5866571A (en) 1999-02-02
HU9600107D0 (en) 1996-03-28
CN1138583A (zh) 1996-12-25
CZ16896A3 (en) 1996-08-14
SG47379A1 (en) 1998-04-17
CA2167349A1 (en) 1996-07-20
BG61729B1 (bg) 1998-04-30
BR9600149A (pt) 1998-01-06
AU4097796A (en) 1996-07-25
SV1996000004A (es) 1997-02-19
NO960221L (no) 1996-07-22
MA23779A1 (fr) 1996-10-01
TNSN96005A1 (en) 2005-03-15
FI960226A (fi) 1996-07-20
PE10597A1 (es) 1997-06-13
TR199600701A2 (tr) 1996-08-21
CO4700524A1 (es) 1998-12-29
ZA96399B (en) 1996-08-14
HUP9600107A2 (en) 1997-05-28
PL312353A1 (en) 1996-07-22
NO960221D0 (no) 1996-01-18
JPH08231546A (ja) 1996-09-10
SK7696A3 (en) 1996-08-07
HRP960009A2 (en) 1997-12-31
BG100291A (bg) 1996-07-31
FI960226A0 (fi) 1996-01-17
EE9600020A (et) 1996-08-15

Similar Documents

Publication Publication Date Title
KR960029335A (ko) 9-치환된 2-(2-n-알콕시페닐)-푸린-6- 온
RU2004120553A (ru) Производные никотинамида, полезные в качестве р38-ингибиторов
PE20030129A1 (es) Imidazotriazinas
RU92004336A (ru) Водорастворимые производные камптотецина, способ их получения, фармацевтическая композиция, способ ингибирования энзима топоизомеразы, промежуточные продукты
HUP0201646A2 (hu) Új alfa-aminosav vegyületek, eljárás ezek előállítására, és ezeket tartalmazó gyógyászati készítmények
ATE247654T1 (de) Neue heterozyklische verbindungen
FI875091A0 (fi) Rebekkamycinanaloger.
KR900006300A (ko) 피리미딘디온 유도체, 이것의 제조방법 및 이것을 함유한 항부정맥제
KR930002372A (ko) 약리학적으로 활성인 히드라진 유도체 및 이의 제조방법
ES8802153A1 (es) Procedimiento para preparar derivados de isoxazol y furano.
ES8203845A1 (es) Procedimiento para preparar derivados de piridoxina
RU2007101497A (ru) Алкилзамещенные индолхиноксалины
KR900003156A (ko) 진통제 화합물, 그의 제조방법 및 그를 함유하는 약학 조성물
KR920701177A (ko) 3-아릴옥사졸리디논 유도체, 그의 제조 방법 및 그의 치료 용도
KR910004568A (ko) 치환 n-(퀴놀린-2-일-메톡시)벤질-술포닐우레아
ES430119A1 (es) Procedimiento para la preparacion de nuevos derivados de 2-fenilamino-imidazolina-(2).
BE901239A (fr) Nouveaux derives d'aminoguanidine et procede pour leur preparation.
RU97115107A (ru) Бициклические производные изотиомочевины, применяемые в терапии
IE44765L (en) N-substituted benzamides.
ES2109216T3 (es) Un procedimiento para la preparacion de una composicion farmaceutica con actividad relajante muscular de accion central.
KR880009015A (ko) 알리머켑토아세틸시드논이민, 이의 제조방법 및 이의 용도
KR920006346A (ko) 3-(1h-인다졸-3-일)-4-피리딘아민, 이의 제조방법, 이의 제조를 위한 중간체 및 약제로서의 이의 용도
ATE5480T1 (de) Thiazolo(3,2-a)pyrimidinderivate, ihre herstellung und arzneimittel, die diese derivate enthalten.
KR850007590A (ko) 4-(니트로페닐)-테트라히드로피리딘류의 제조방법
NO803547L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-fenylamino-imidazolin-derivater

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid